ClearCell® FX1 System
Driven by CTChip® FR
The ClearCell® FX1 System, driven by the CTChip® FR, is one of the world’s first automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in a relatively short time.
Combined with the high levels of purity, the CTCs are enriched in suspension, which allows for easy integration with downstream molecular analyses and diagnostic assays. This means that researchers and clinicians can use these insights to provide timely, tailored treatment options.
NewsGenomeWeb Feature: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership to develop CTC CoRE in the U.S. PR Newswire: John Wayne Cancer Institute, and Clearbridge BioMedics announce partnership to develop Circulating Tumor Cell Centre of Research Excellence in the U.S. BioSpectrum: John Wayne Cancer Institute and Clearbridge BioMedics announce partnership
22-23 AUGUST 2017 | SEOUL, S.KOREA | PRESENTATION & BOOTH #3Read more